Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Zora Biosciences commercializes VTT's biotechnology expertise

21.06.2007
VTT Technical Research Center of Finland has spun-off Zora Biosciences Oy, the only company in the Nordic countries to offer metabolomics services to drug developers. Zora also develops biomarkers, which, for example, make it possible to detect early signs of cardiovascular disease.

VTT Technical Research Center of Finland has launched a spin-off company, Zora Biosciences Oy. "Zora's speciality field of metabolomics is a major driver of biomedical and pharmaceutical research", says Matej Orešic, founder and chairman of the board.

Zora's business model is two-fold. Zora will provide sophisticated laboratory services to pharmaceutical industry in the area of metabolomics and associated bioinformatics. Also, based on this advanced laboratory expertise Zora will develop prognostic and diagnostic biomarkers for human diseases as well as drug safety and efficacy monitoring.

Zora will aggressively expand its biomarker portfolio for licensing the discoveries to laboratory assay providers. At present, Zora's biomarker portfolio includes a promising discovery for screening patients susceptible to side effects of statins, which are powerful cholesterol lowering drugs. Statin medication is used by millions world-wide as part of their treatment regimen for cardiovascular diseases. Zora is also developing prognostic and diagnostics tools for improved healthcare management of diabetes and coronary artery disease among other indication areas.

... more about:
»Biomarker »Biosciences »metabolomics

Zora is funded by VTT, Slovenian private investor Gomar D.D., and Seedcap II Ky, managed by Innofinance Oy. "Zora has strong potential for rapid business growth and internationalization, which has attracted a committed investor base for the company", says Reini Hurme, Zora CEO. Globally there is only a handful of companies specializing in metabolomics, in the Nordic countries Zora is the only one.

Zora Biosciences Oy

Zora Biosciences offers advanced laboratory services for the needs of the pharmaceutical industry in the fields of metabolomics and bioinformatics. Based on this advanced laboratory competence, Zora also develops prognostic and diagnostic biomarkers for disease diagnosis and monitoring of the efficacy and safety of drugs.

Press Office | alfa
Further information:
http://www.zora.fi
http://www.vtt.fi/?lang=en

Further reports about: Biomarker Biosciences metabolomics

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>